Shionogi
4507.T
Performance
About Shionogi
Shionogi BV operates as the European headquarters of the global pharmaceutical group Shionogi, focused on developing and marketing medicines to address unmet medical needs. Based in Germany with an established presence in Europe, the company emphasizes infectious diseases, anti-infectives, pain management, and women’s health, leveraging internal R&D as well as strategic collaborations. It positions itself as a leader in addressing global health challenges, including the development of potential antibiotics against multi-drug resistant bacteria. The site highlights its commitment to patient welfare and collaboration with healthcare partners across Europe.
Recent News
Leqembi Starts to Deliver for Eisai and Biogen
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions
Shionogi Secures $482m BARDA Contract to Tackle AMR Crisis
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
Pfizer to Depart GSK's ViiV as Shionogi Doubles Its Stake
Pharmaceutical Executive Daily: Leadership Turnover Under Trump Administration
ViiV Ownership Shifts as Pfizer Sells Its Stake
Teladoc’s Mental Health Arm BetterHelp Has Quietly Expanded the Use of AI
